JP2015525754A - 化合物１−（６−｛［６−（４−フルオロフェニル）［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン−３−イル］スルファニル｝−１，３−ベンゾチアゾール−２−イル）−３−（２−モルホリン−４−イルエチル）尿素を含む抗腫瘍組成物 - Google Patents

化合物１−（６−｛［６−（４−フルオロフェニル）［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン−３−イル］スルファニル｝−１，３−ベンゾチアゾール−２−イル）−３−（２−モルホリン−４−イルエチル）尿素を含む抗腫瘍組成物 Download PDF

Info

Publication number
JP2015525754A
JP2015525754A JP2015521001A JP2015521001A JP2015525754A JP 2015525754 A JP2015525754 A JP 2015525754A JP 2015521001 A JP2015521001 A JP 2015521001A JP 2015521001 A JP2015521001 A JP 2015521001A JP 2015525754 A JP2015525754 A JP 2015525754A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
dose
urea
ylethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015521001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015525754A5 (enExample
Inventor
ジャン−ルネ・オーテラン
シルヴィ・アッサドゥーリアン
ツィアラ・ベナール
エレーヌ・ゴーラウィク
アマンディーヌ・マチュー
マリア−テレサ・ペラッチア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2015525754A publication Critical patent/JP2015525754A/ja
Publication of JP2015525754A5 publication Critical patent/JP2015525754A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2015521001A 2012-07-12 2013-07-11 化合物１−（６−｛［６−（４−フルオロフェニル）［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン−３−イル］スルファニル｝−１，３−ベンゾチアゾール−２−イル）−３−（２−モルホリン−４−イルエチル）尿素を含む抗腫瘍組成物 Pending JP2015525754A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305840 2012-07-12
EP12305840.6 2012-07-12
PCT/EP2013/064741 WO2014009500A1 (en) 2012-07-12 2013-07-11 Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea

Publications (2)

Publication Number Publication Date
JP2015525754A true JP2015525754A (ja) 2015-09-07
JP2015525754A5 JP2015525754A5 (enExample) 2016-08-12

Family

ID=48782350

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015521001A Pending JP2015525754A (ja) 2012-07-12 2013-07-11 化合物１−（６−｛［６−（４−フルオロフェニル）［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン−３−イル］スルファニル｝−１，３−ベンゾチアゾール−２−イル）−３−（２−モルホリン−４−イルエチル）尿素を含む抗腫瘍組成物

Country Status (25)

Country Link
US (1) US20150119391A1 (enExample)
EP (1) EP2872119A1 (enExample)
JP (1) JP2015525754A (enExample)
KR (1) KR20150030761A (enExample)
CN (1) CN104470500A (enExample)
AR (1) AR091727A1 (enExample)
AU (1) AU2013288676A1 (enExample)
BR (1) BR112015000497A2 (enExample)
CA (1) CA2878500A1 (enExample)
CL (1) CL2015000074A1 (enExample)
CO (1) CO7160069A2 (enExample)
CR (1) CR20150005A (enExample)
EA (1) EA201590199A1 (enExample)
HK (1) HK1209642A1 (enExample)
IL (1) IL236662A0 (enExample)
IN (1) IN2015KN00075A (enExample)
MA (1) MA37753B1 (enExample)
MX (1) MX2015000532A (enExample)
PH (1) PH12015500060A1 (enExample)
SG (1) SG11201500123XA (enExample)
TN (1) TN2015000011A1 (enExample)
TW (1) TW201402121A (enExample)
UY (1) UY34909A (enExample)
WO (1) WO2014009500A1 (enExample)
ZA (1) ZA201500129B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024544083A (ja) * 2021-12-15 2024-11-27 シルラジェン，インコーポレイテッド 修飾ベータ－シクロデキストリンを含む医薬組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517540A (ja) * 2003-01-14 2006-07-27 テバ ファーマシューティカル インダストリーズ リミティド 全身性エリテマトーデスの治療のためのペプチドの非経口製剤
JP2010535747A (ja) * 2007-08-09 2010-11-25 サノフイ−アベンテイス 新規な６−トリアゾロピリダジンスルファニルベンゾチアゾールおよびベンゾイミダゾールの誘導体、これらの製造方法、薬剤および医薬組成物としての適用ならびにｍｅｔ阻害剤としての新規な使用
JP2011513201A (ja) * 2008-02-28 2011-04-28 武田薬品工業株式会社 医薬組成物
JP2012514012A (ja) * 2008-12-31 2012-06-21 ナンジン キャベンディッシュ バイオ−エンジニアリング テクノロジー カンパニー，リミテッド ボリコナゾール含有の薬物製剤及びその調製方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2817750B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517540A (ja) * 2003-01-14 2006-07-27 テバ ファーマシューティカル インダストリーズ リミティド 全身性エリテマトーデスの治療のためのペプチドの非経口製剤
JP2010535747A (ja) * 2007-08-09 2010-11-25 サノフイ−アベンテイス 新規な６−トリアゾロピリダジンスルファニルベンゾチアゾールおよびベンゾイミダゾールの誘導体、これらの製造方法、薬剤および医薬組成物としての適用ならびにｍｅｔ阻害剤としての新規な使用
JP2011513201A (ja) * 2008-02-28 2011-04-28 武田薬品工業株式会社 医薬組成物
JP2012514012A (ja) * 2008-12-31 2012-06-21 ナンジン キャベンディッシュ バイオ−エンジニアリング テクノロジー カンパニー，リミテッド ボリコナゾール含有の薬物製剤及びその調製方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024544083A (ja) * 2021-12-15 2024-11-27 シルラジェン，インコーポレイテッド 修飾ベータ－シクロデキストリンを含む医薬組成物

Also Published As

Publication number Publication date
AU2013288676A1 (en) 2015-02-05
ZA201500129B (en) 2015-12-23
CL2015000074A1 (es) 2015-06-12
CN104470500A (zh) 2015-03-25
SG11201500123XA (en) 2015-02-27
AR091727A1 (es) 2015-02-25
UY34909A (es) 2013-11-29
EP2872119A1 (en) 2015-05-20
CO7160069A2 (es) 2015-01-15
US20150119391A1 (en) 2015-04-30
MA37753A3 (fr) 2018-05-31
IL236662A0 (en) 2015-02-26
CA2878500A1 (en) 2014-01-16
MA37753A2 (fr) 2016-06-30
TW201402121A (zh) 2014-01-16
MA37753B1 (fr) 2019-04-30
KR20150030761A (ko) 2015-03-20
IN2015KN00075A (enExample) 2015-07-31
TN2015000011A1 (en) 2016-06-29
HK1209642A1 (en) 2016-04-08
BR112015000497A2 (pt) 2017-06-27
MX2015000532A (es) 2015-05-15
PH12015500060A1 (en) 2015-03-02
WO2014009500A1 (en) 2014-01-16
EA201590199A1 (ru) 2015-05-29
CR20150005A (es) 2015-04-06

Similar Documents

Publication Publication Date Title
JP7482180B2 (ja) 癌のための併用療法
CN115515577A (zh) 用于治疗癌症的atr抑制剂
BR112019015011A2 (pt) combinações de cabozantinibe e atezolizumabe para tratar câncer
JP5449784B2 (ja) 抗癌用途のためのドキソルビシン製剤
KR20200128101A (ko) 궤양성 결장염을 치료하는 방법
US10975146B2 (en) Interleukin-1 inhibition for combination treatment of pancreatic cancer
JP2022079545A (ja) リポソーマルイリノテカンによる乳がんの治療
KR20160021084A (ko) 사람에서 고형 종양의 치료를 위한 씨. 노비
US11058673B2 (en) Dosage regimen of MDM2 inhibitor for treating cancers
KR20250069693A (ko) 암 치료
US20240025986A1 (en) Therapy for glaucoma and optic neuropathy by targeting colony stimulating factors
TW202123935A (zh) 用於奈米粒子組合物之生物標記
KR20200065093A (ko) 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법
TW202045173A (zh) 癌症治療
Schöffski et al. BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study
JP2022512158A (ja) 免疫調節を使用したがんの治療のための新規アプローチ
WO2025103408A1 (zh) 治疗alk阳性或ros1阳性的非小细胞肺癌的方法
JP2019511541A (ja) 結腸直腸癌の処置における使用のためのラムシルマブとメレスチニブとの組み合わせ
US20150119391A1 (en) Anti-tumoral composition comprising the compound 1-(6--1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea
EP2755655A1 (en) Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients
Subudhi A pilot trial to explore the link between immunological changes, efficacy, safety and tolerability of durvalumab (MEDI4736) plus tremelimumab in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (CRPC)
JP2019513767A (ja) マントル細胞リンパ腫の治療における使用のためのラムシルマブ及びアベマシクリブの組み合わせ療法
Sequist et al. A phase 1b study of osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small cell lung cancer after progression on EGFR-tyrosine kinase inhibitors
CN109939094B (zh) 用于治疗胰腺癌的治疗性组合物
Vita et al. 1363P Genomic heterogeneity of ALK rearrangements and acquired resistance pathways in ALK+ Advanced non-small cell lung cancer (NSCLC) treated with upfront alectinib: Preliminary results of GALILEO project

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170321

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171010